Regional recurrence in the era of sentinel lymph node biopsy

Abstract Background The incidence of all-location regional recurrence after sentinel lymph node biopsy is not well documented. This study attempts to identify risk factors. Methods A prospectively maintained database was queried to identify patients with a regional recurrence of breast cancer after...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The American journal of surgery 2015-12, Vol.210 (6), p.1155-1161
Hauptverfasser: Linnaus, Maria E., M.D, Dueck, Amylou C., Ph.D, Kosiorek, Heidi E., M.S, Gray, Richard J., M.D, Wasif, Nabil, M.D, Northfelt, Donald W., M.D, Anderson, Karen S., M.D., Ph.D, McCullough, Ann E., M.D, Wong, William W., M.D, Halyard, Michele Y., M.D, Patel, Samir H., M.D, Pockaj, Barbara A., M.D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background The incidence of all-location regional recurrence after sentinel lymph node biopsy is not well documented. This study attempts to identify risk factors. Methods A prospectively maintained database was queried to identify patients with a regional recurrence of breast cancer after a first operation for invasive unilateral breast cancer. Patients with regional recurrence were compared with those alive and disease free at 5 years. Results Twenty-one of 1,060 patients (2%) experienced a regional recurrence. Most patients (95%) underwent sentinel lymph node biopsy as their axillary staging. Those with regional recurrences had larger tumors ( P < .001), higher stage disease ( P < .001), more estrogen receptor– and triple-negative breast cancers ( P < .001), and more positive lymph nodes ( P = .007). Mastectomy ( P = .001) and receipt of neoadjuvant and/or chemotherapy ( P < .001) were more common among those with regional recurrences. Conclusions Regional recurrence of breast cancer occurs infrequently. Risk factors include high-risk cancers, higher stage at presentation, nodal involvement, and need for therapies reflecting higher risk biology.
ISSN:0002-9610
1879-1883
DOI:10.1016/j.amjsurg.2015.09.001